Acute Complications in Chronic Kidney Disease: Emergency Management
Patients with CKD are at high risk for acute-on-chronic kidney injury, and immediate management must focus on identifying and treating life-threatening metabolic derangements, optimizing hemodynamics, and eliminating nephrotoxic exposures to prevent progression to kidney failure.
Life-Threatening Indications for Emergency Renal Replacement Therapy
Initiate RRT emergently when metabolic and fluid demands exceed kidney capacity, specifically for 1:
- Refractory hyperkalemia (typically >6.5 mEq/L with ECG changes)
- Severe metabolic acidosis (pH <7.1 or bicarbonate <10 mEq/L)
- Uremic complications (pericarditis, encephalopathy, bleeding)
- Fluid overload unresponsive to diuretics causing pulmonary edema or respiratory compromise
In hemodynamically unstable patients, continuous RRT is more physiologically appropriate than intermittent hemodialysis, though outcomes data do not show superiority 1.
Hemodynamic Optimization and Fluid Management
Vasopressor Support
Combine vasopressors with fluid resuscitation for hypotension or vasomotor shock; fluids alone are insufficient to restore renal perfusion pressure 2. Use norepinephrine as first-line vasopressor and target mean arterial pressure ≥65 mmHg to ensure adequate renal perfusion 2.
Fluid Resuscitation Strategy
Administer balanced/buffered crystalloids (lactated Ringer's, Plasma-Lyte) as initial volume-expanding agents rather than 0.9% saline 2. Large saline volumes cause hyperchloremic acidosis and renal vasoconstriction, worsening AKI 2. Multiple trials demonstrate that balanced solutions lower major adverse kidney events compared with saline 2.
Avoid hydroxyethyl starch solutions as they directly increase AKI risk 2. Reserve albumin for specific indications only (spontaneous bacterial peritonitis, large-volume paracentesis, hepatorenal syndrome) 2.
Volume Status Monitoring
Maintain euvolemia—prevent both hypovolemia and fluid overload, as positive cumulative fluid balance is linked to higher mortality and prolonged AKI duration 2. Continuously monitor fluid accumulation using daily weights and bedside ultrasound, adjusting administration accordingly 2.
Immediate Nephrotoxin Management
Systematically review all medications and immediately discontinue or dose-adjust any non-essential nephrotoxic drugs 3, 2. The "triple whammy" combination of NSAIDs, diuretics, and ACE inhibitors/ARBs more than doubles AKI risk 3.
Specific Nephrotoxins to Address
- Avoid NSAIDs completely in CKD patients with creatinine clearance <30 mL/min 3
- Avoid aminoglycosides unless no alternative exists; if required, use once-daily dosing with therapeutic drug monitoring 2
- Hold ACE inhibitors/ARBs during acute illness, though evidence shows failure to restart after acute episodes may increase 30-day mortality 2
- Avoid macrolide-statin combinations (clarithromycin/erythromycin with statins) that cause rhabdomyolysis-induced AKI 3
Trimethoprim-sulfamethoxazole is not recommended if creatinine clearance is <15 mL/min 3.
Diuretic Management in Volume Overload
Diuretics may be employed only to treat established volume overload in patients with sufficient residual kidney function 2. Avoid diuretics in hypovolemic patients as they exacerbate renal hypoperfusion 2. Do not use diuretics solely to prevent AKI—they are ineffective for this purpose 2.
If diuretics fail to achieve adequate fluid removal, consider ultrafiltration or renal replacement therapy 2.
Pharmacologic Agents to Avoid
The following agents have no role in acute CKD complications and should not be used 2:
- Low-dose dopamine (strong recommendation against)
- Fenoldopam
- Atrial natriuretic peptide (ANP)
- N-acetylcysteine for postoperative AKI prophylaxis
Metabolic and Electrolyte Management
Glycemic Control
Target plasma glucose 110–149 mg/dL (6.1–8.3 mmol/L) in critically ill CKD patients to avoid hyper- or hypoglycemia-related kidney injury 2.
Nutritional Support
Provide 20–30 kcal/kg/day of total energy and 1.0–1.5 g/kg/day of protein (up to 1.7 g/kg/day if hypercatabolic or on RRT) 2. Do not restrict protein intake to delay dialysis initiation 2. Prefer enteral nutrition over parenteral routes whenever feasible 2.
Chronic Complications Requiring Monitoring
Evaluation and treatment of CKD complications should be undertaken when GFR declines to <60 mL/min per 1.73 m² (Stage 3), as prevalence rises at this threshold 4:
- Anemia (consider erythropoietin therapy)
- Metabolic acidosis (bicarbonate supplementation)
- Hyperphosphatemia and bone disease (phosphate binders, vitamin D analogues)
- Hyperkalemia (dietary restriction, potassium binders)
- Secondary hyperparathyroidism (calcium supplementation, vitamin D)
Biomarker-Guided Risk Stratification
When urinary TIMP-2 × IGFBP7 ≥0.3 (ng/mL)²/1000, implement a bundled care pathway including nephrotoxin avoidance, close creatinine/urine output monitoring, prevention of hyperglycemia and contrast exposure, and optimization of volume status and hemodynamics 2. Patients with oliguria but TIMP-2 × IGFBP7 <0.3 do not have increased AKI progression risk 2.
Specialist Referral Thresholds
Nephrologist consultation should occur when GFR <30 mL/min per 1.73 m² (Stage 4) 4. Preparation for kidney replacement therapy should begin during Stage 4, well before uremic symptoms develop 4. Late referral is associated with increased mortality after dialysis initiation 4.
Critical Pitfalls to Avoid
- Do not interpret oliguria as automatic hypovolemia—indiscriminate fluid boluses can produce harmful overload 2
- Serum creatinine can be misleading during acute volume changes as large-volume resuscitation dilutes creatinine, potentially delaying AKI detection 2
- Patients with CKD entering acute kidney disease (AKD) phase require continued nephrotoxin avoidance even during recovery to prevent re-injury 3
- CKD is a major risk factor for AKI, and AKI significantly accelerates CKD progression 3, 5